Economic impact of antimicrobial resistance.

John E McGowan Jr., Emory University

Journal Title: Emerging Infectious Diseases
Volume: Volume 7, Number 2
Publisher: U.S. National Center for Infectious Diseases | 2001-03, Pages 286-292
Type of Work: Article | Final Publisher PDF
Permanent URL: http://pid.emory.edu/ark:/25593/fm7hg

Final published version: http://wwwnc.cdc.gov/eid/

Copyright information:
Emerging Infectious Diseases is published by the Centers for Disease Control and Prevention, a U.S. Government agency. Therefore, all materials published in Emerging Infectious Diseases are in the public domain and can be used without permission.

Accessed February 5, 2020 6:07 AM EST
Economic Impact of Antimicrobial Resistance

John E. McGowan, Jr.
Emory University School of Medicine, Atlanta, Georgia, USA

One reason antimicrobial-drug resistance has recently become a concern is its economic impact. The Institute of Medicine estimates the annual cost of infections caused by antibiotic-resistant bacteria to be U.S.$4 to $5 million (1). However, methods for measuring economic impact of resistance are in their infancy, and the studies leave many questions unanswered (2). In this review, I examine perspectives from which economic impact of resistance is important, assess available data about economic methods used for evaluating economic effect, and suggest issues important for these assessments, as well as approaches for further study.

Economic Impact: Differing Viewpoints

Several viewpoints toward antimicrobial-drug resistance and its impact include those of physicians, patients, health-care businesses, the drug industry, and the public (Table 1).

Physicians

The view most considered in day-to-day medical care is that of the practicing physician. Physicians focus on individual patients and are motivated by professionalism that demands they seek the absence of disease, most often in persons who are ill when they visit a physician. Thus, the main economic problems that resistance presents for physicians are related to ineffective treatment (e.g., consequences arising from patient death, disease). From this treatment perspective, a production model of the type presented by Scott (3) would relate the existence of multiple antimicrobial agents to likely effectiveness in curing a given patient's infection. To clinicians treating individual patients, availability of more antimicrobial agents than needed would be of little or no concern. However, clinicians would be alarmed by absence of effective agents (the “postantibiotic era” cited frequently since Cohen's publication of that title [4] in 1992). From this viewpoint, the economic impact of diminishing effectiveness of a given drug or group of drugs depends on the availability of other drugs.

Patients

Patients with infections are likely to have a view similar to that of the physician (Table 1), except that their motivation for participating in the treatment process is their own well-being. Economic impact is also measured in terms of consequences arising from illness and death, specifically the added cost of treatment of a resistant organism, since patients pay retail prices for drugs and services. Such charges are assumed directly when patients pay their own bills or absorbed indirectly when added costs of multiple drugs and services result in increasing premiums for patients who have health-care coverage.

Health-Care Businesses

Today, health-care system financial resources in the United States are less frequently controlled by doctors and nurses and more often by administrators, financial managers, third-party payers, and politicians. These people see reduced illness and death as a reasonable goal, but also seek objective evidence that this goal is achieved with fiscal efficiency (i.e., by the least expenditure of increasingly scarce financial resources [5]). Antimicrobial drugs represent a way to provide cost-effective care to patients who are part of a defined population being served. The economic cost of antimicrobial-drug resistance for health-care businesses is in the measures they must take to preserve the effectiveness of antimicrobial agents in the care group. These measures may include costs for a series of different drugs and services, as well as for personnel time, supplies, space, and equipment for institutional programs to deal with antimicrobial-drug resistance (e.g., pharmacy and therapeutics committees.

Table 1. Perspectives of economic impact of antimicrobial-drug resistance

<table>
<thead>
<tr>
<th>Focus</th>
<th>Outcome</th>
<th>Time</th>
<th>Motivation</th>
<th>Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician</td>
<td>Individual Health</td>
<td>Short</td>
<td>Professionalism</td>
<td>Treatment</td>
</tr>
<tr>
<td>Patient</td>
<td>Individual Health</td>
<td>Short</td>
<td>Health</td>
<td>Treatment</td>
</tr>
<tr>
<td>Provider</td>
<td>Care group Lower cost</td>
<td>Short</td>
<td>Profit</td>
<td>Cost containment</td>
</tr>
<tr>
<td>Industry</td>
<td>Clients Sales</td>
<td>Short, long</td>
<td>Profit</td>
<td>New drugs, viable old drugs</td>
</tr>
<tr>
<td>Public</td>
<td>Population Health Long</td>
<td>Social good</td>
<td>Lower chance of resistance</td>
<td></td>
</tr>
</tbody>
</table>

Drug Industry

The focus for pharmaceutical firms and other groups providing products for treatment and prevention of infectious diseases (e.g., antimicrobial agents, products to stimulate host defenses, vaccines) is similar to that of the health-care business. This group is also motivated by profit and focuses on potential clients; however, the clients of interest are the potential users of their products--direct (patients) and indirect (health-care systems, governments, and the like) rather than enrolled subscribers to a health plan. Product sales are the desired outcome, and a short-term view of sales is part of their outlook. However, industry must also take a longer view of the subject and consider the impact of resistance as potential for introduction and sale of new products, necessitating a two-pronged approach. On the one hand, firms wish to maintain the life of their current antimicrobial products, a goal threatened by new patterns of antimicrobial-drug resistance. On the other hand, resistance may make obsolete a competitor's product, opening up the field for a product that may have been less marketable because it cost more or was less safe or effective. In addition, resistance to drugs may produce a niche for a new antimicrobial agent.

Public (“Societal View”)

A final view to be considered is that of public health or the public good. This societal perspective, fueled by the goal of social good, encompasses entire populations, whether of towns, cities, countries, and even the entire world. As the goal here is to maximize health for the whole population, the time frame is usually long term. Since antimicrobial drugs enhance both prevention and treatment of infections, society considers them a valuable resource. As resistance diminishes this resource, a societal goal would be to minimize resistance and therefore the forces that produce resistance.

In the jargon of economics, antimicrobial agents are a scarce resource, that is, one in which consumption (current use) decreases its effectiveness (future value) (6). Any use of antimicrobial agents enhances the likelihood of resistance. From a societal viewpoint, then, appropriate use of antimicrobial drugs for treatment and prevention of infection would lead to an appropriate or acceptable decrease in the value of antimicrobial effectiveness. Conversely, overuse or misuse of antimicrobial drugs would create an inappropriate decrease in these resources. When treating one person leads to decreased effectiveness in treating the next person receiving the drug, society is affected adversely. This impact is often ignored because the short-term outcome and cost of drugs (for example, for perioperative prophylaxis) can be measured readily, and the detrimental effect on long-term usefulness is unquantified for most situations (7).

Whose Perspective?

The economic costs and benefits of programs to preserve antimicrobial effectiveness must be interpreted in the context of these differing points of view. In any single study, it is essential to keep the same perspective, whichever it may be. Analyses that mix the different points of view in assessment tend to confuse rather than clarify the problem and its extent. For example, the business viewpoint might value loss of effectiveness of a cheap antimicrobial agent as important when it leads to use of a more expensive agent for patient care. In contrast, the medical viewpoint might find loss of effectiveness of the cheaper drug of little consequence as long as other effective drugs are available.

Similarly, the value of antimicrobial effectiveness might differ from an economic viewpoint rather than the medical one. For example, from a public health perspective, the use of antimicrobial agents to promote growth in animals would be evaluated by comparing the relative benefit to food production against the potential for decreasing the effectiveness of prevention and treatment of infections in humans. In contrast, the physician’s perspective would evaluate the use of antimicrobial agents in animals in terms of its impact on the effectiveness of specific medical therapeutic agents.

A third example of varying perspectives is the use of measures to control the physician’s choice of antimicrobial agents. This step may make great sense to hospital or other health-care administrators when it is likely to produce more efficient use of resources. Yet the control measures might be seen as having no value by clinicians who are willing to use any and all resources to cure their patients.

Assessing the Economic Impact of Resistance

Net economic impact of resistance can be viewed as the attributable cost of treatment of an infection due to a resistant isolate (“treatment cost”) minus the cost of preventing such infections (“prevention cost”). Cost analysis should include consideration of all resources affected by illness or intervention (8). Economic impact of antimicrobial-drug resistance includes a wide range of factors important to various viewpoints (Table 2). The difference in this situation is the added cost for each element associated with infection with a resistant organism compared with the cost for the same element if associated with infection caused by a susceptible microbe (Table 2).

Costs for laboratory tests, radiologic studies, bronchoscopies, or other diagnostic procedures are part of diagnostic costs and primarily of concern to the health-care institution when these costs cannot be passed on to the patient or an insurer. The same is true of costs for purchase and administration of antimicrobial drugs and other therapeutic agents. Patients experience both direct costs of health care and indirect costs (e.g., loss of productivity resulting in reduction in income). Other types of indirect costs of antimicrobial-drug resistance are costs to the drug industry resulting from diminishing marketability of their drugs and costs to businesses for loss of workers’ productive time. All these factors are part of the economic impact of resistance.

Studies of the economic impact of resistance have not included measurement of most of these variables. They have
usually focused on hospital charges and length of stay, features that are objective and relatively easy to collect compared with other aspects of impact. Recent studies of impact have also included estimates of increased hospital or other institutional stay, incremental specific treatments, and additional diagnostic tests needed for a patient infected with a resistant organism compared with a patient infected with a strain of the same organism that is drug susceptible (Table 3) (9-23). Attempts have also been made to measure death and illness associated with resistant infections. Although these are objective indicators of economic impact, until recently it was impractical to obtain this information on the small patient groups studied at individual hospitals or other single health-care settings. In addition, few studies have been published on the impact of antimicrobial-drug resistance outside health-care locations. Further attention is needed to the community setting, where much of antimicrobial treatment is given and received (24).

Generalizations from single-center studies are hindered by differences in local practices. For example, some centers experience delays in transferring patients with positive cultures for vancomycin-resistant enterococci or methicillin-resistant Staphylococcus aureus (MRSA) from acute-care centers to long-term care facilities (25). Estimates of incremental increase in length of hospital stay for these institutions might differ from those where such problems do not exist. Thus, multicenter studies would be needed to obtain data that could be used to generalize about regional or national estimates of impact.

Determining the economic impact of antimicrobial-drug resistance to a given drug may have several facets (26). The relative benefit of being able to use a given drug in comparison with alternatives when this drug is not available must be assessed. Thus, to decide the worth of an antimicrobial drug, several elements must be considered. The incremental cost of treating the patient with alternative agents must be assessed, often by studies in which costs for care of patients infected with isolates resistant to a commonly used agent

| Table 2. Elements of the economic impact of antimicrobial-drug resistance, by perspective affected |
|-----------------------------------------------|-------------------------------------------------|-----------------------------------------------|
| Element                                      | Measurement                                      | Perspective affected                          |
| Death                                        | [Costs associated with treatment failure (R)] - [Costs associated with treatment failure (S)] | Physician, patient, HCB                      |
| Illness                                      | [Costs associated with pain, suffering, inconvenience (R)] - [Costs associated with pain, suffering, inconvenience (S)] | Physician, patient                           |
| Care cost                                    | [Charges for care (R)] - [Charges for care (S)]  | Patient                                       |
| Care time                                    | [Time devoted to care (R)] - [Time devoted to care (S)] | Physician, HCB                               |
| Diagnosis costs                              | [Costs for process (R)] - [Costs for process (S)] | Patient, society                             |
| Treatment costs                              | [Costs for drugs (additional drugs and treatments, more expensive drugs (R)] - [Costs for drugs (S)] | HCB                                           |
| Diminished marketability                      | [Market for drug use (R)] - [Market for drug use (S)] | Drug industry                                 |
| New markets                                  | [Market for new drug (S)] - [New market for new drug (R)] | Drug industry                                 |
| Impact on non-treated                        | [Increased resistance (R)] - [Increased resistance (S)] | Society                                       |

*R = extent in patients infected with resistant organism; S = extent in patients infected with susceptible organism; HCB = health-care business.

Costs associated with lack of routine functions during infection, including loss of work, quality of life for patient (includes both inpatient and outpatient components); for society, reduction of useful function in workforce.

| Table 3. Examples of studies of economic impact of resistance published in 1999-2000 |
|-----------------------------------------------|-----------------------------------------------|
| Year                                         | First author (ref.) | Study methods | Features measured |
| 2000                                         | Soriano (9)          | Case-control, cohort | Death, length of hospital stay |
| 2000                                         | Roghmann (10)        | Cohort         | Mortality rates at 7 & 30 days, length of hospital stay, direct health-care costs |
| 2000                                         | Vanhems (11)         | Cohort         | Death |
| 2000                                         | Simor (12)           | Comparison of cases with arbitrary criteria | Incremental length of hospital stay |
| 2000                                         | Harthug (13)         | Case-control   | Death |
| 2000                                         | Bhavnani (14)        | Case-control   | Death |
| 2000                                         | Feikin (15)          | Cohort         | Death |
| 2000                                         | Garbutt (16)         | Retrospective case control | Death |
| 1999                                         | Carmeli (17)         | Cohort         | Death, length of hospital stay, hospital charges |
| 1999                                         | Rubin (18)           | Modeling, assumption and extrapolation from case reports | Death, direct medical costs |
| 1999                                         | Weingarten (19)      | Case-control   | Use of ventilators, length of hospital stay, duration and number of antimicrobial agents, pharmacy charges |
| 1999                                         | Gonzalez (20)        | Cohort         | Death |
| 1999                                         | Abramson (21)        | Case-control   | Length of hospital stay, attributable median total cost |
(drug X) are compared with costs for care of patients with isolates that are susceptible to drug X. A potential problem with this type of comparison is that a uniform reference group is not readily available. For example, a study may compare costs for care of patients with susceptible isolates treated with drug X to costs for patients infected with isolates resistant to drug X who are then treated with one or more alternative drugs (e.g., Y,Z), when choice of drug is left to the patient's physician. However, other factors (such as altered renal function or a patient's inability to take oral medications) leading to use of drugs Y or Z to treat patients infected with resistant organisms may also have led to treatment with one of these drugs in patients infected with susceptible organisms. Thus, costs must be evaluated carefully to compare these two groups of patients and account for other factors affecting therapy. Study design may also influence the measured impact of resistance (27,28).

Current Situation
For these and other reasons, measurement of the economic impact of resistance is imprecise and incomplete. Neither methods for direct measurement nor appropriate surrogate variables have been found for some important features. Methods used have primarily focused on case-control strategies, which have limitations (27).

Further work needed on this aspect of the question includes defining optimal methods of measurement, including more aspects of economic impact, and disclosing the perspective from which the assessment is being made. Measurement of impact of resistance on patients through cost-utility analysis may be helpful as well (29).

Measuring Benefit of Programs to Minimize Resistance

Steps to Minimize Antimicrobial-Drug Resistance and Its Economic Impact
Several strategies and approaches have attempted to deal with resistance (Table 4) (30,31). The term “control” seems inappropriate because true control of antimicrobial-resistant organisms and their effects seems biologically and historically impossible. However, statements from professional societies, independent review groups, and governmental agencies stress several measures to minimize the detrimental effects of resistance (32-35). These include professional educational programs, enhanced microbiologic surveillance, enhanced surveillance of patients, implementation of infection control procedures, development of vaccines against resistant organisms, and prudent use of antimicrobial agents for treatment and prophylaxis. These measures can be evaluated in terms of their success in reducing antimicrobial-drug resistance and its associated costs (36). However, costs associated with each of the strategies must also be included in the calculation of overall economic impact (26). These costs are more or less important, depending on the perspective from which the analysis is being conducted. The few analyses of this type conducted to date focus on costs of infection control (37).

Developing New Antimicrobial Drugs and Other Therapeutic Agents
The most obvious way to combat resistance is to develop new antimicrobial agents (38). Several new combinations or classes of antimicrobial agents now may prove valuable to combat infections caused by resistant bacteria (39,40). Nonantimicrobial means to combat resistant organisms (e.g., development of vaccines) will also assume more importance (41,42).

Economic impact here is primarily a concern for the pharmaceutical industry and consists of the net difference between costs associated with developing new agents and the profit from sale of the agents when they are marketed.

Surveillance for Antimicrobial-Drug Resistance
Surveillance is vital to determining measures needed to control antimicrobial-drug resistance (43). New, rapid laboratory methods are becoming available to facilitate this important effort. Surveillance methods produce expenses in use of diagnostic testing (e.g., microbiologic cultures), and they require additional time for infection control and laboratory personnel, as well as patient care staff, to interact with infection control personnel and implement surveillance programs.

Implementing Infection Control Measures
Approximately 30% to 40% of resistant infections arise from cross-infection via hands of hospital personnel, 20% to

### Table 4. Elements of the economic impact of measures to deal with antimicrobial drug resistance, by perspective affected

<table>
<thead>
<tr>
<th>Element</th>
<th>Measurement</th>
<th>Perspective affected directly</th>
</tr>
</thead>
<tbody>
<tr>
<td>Develop new antimicrobial agents</td>
<td>[Costs associated with drug development] - [Profit resulting from new drug’s use]</td>
<td>Drug industry, HCB, patient, society</td>
</tr>
<tr>
<td>Conduct surveillance</td>
<td>[Cost of surveillance for infected and colonized patients (R)] - [Cost of surveillance for infected and colonized patients (S)]</td>
<td>HCB</td>
</tr>
<tr>
<td>Implement isolation</td>
<td>[Costs associated with barrier isolation (R)] - [Costs associated with barrier isolation (S)]</td>
<td>HCW, visitor, patient, HCB</td>
</tr>
<tr>
<td>Adapt lab procedures</td>
<td>[Costs associated with testing (R)] - [Costs associated with testing (S)]</td>
<td>HCB, patient, society</td>
</tr>
<tr>
<td>Educate about resistance</td>
<td>[Costs associated with educational programs (staff, patients) (R)] - [Costs associated with educational programs (staff, patients) (S)]</td>
<td>HCW, patient, visitor, HCB</td>
</tr>
<tr>
<td>Improve drug administration</td>
<td>[Costs for programs to improve drug administration (R)] - [Costs for programs to improve drug administration (S)]</td>
<td>HCW, HCB</td>
</tr>
<tr>
<td>Improve drug choice</td>
<td>[Costs for programs to improve drug choice (R)] - [Costs for programs to improve drug choice (S)]</td>
<td>Prescribers, HCB</td>
</tr>
</tbody>
</table>

*R = extent in patients infected with resistant organism; S = extent in patients infected with susceptible organism; HCB = health-care business; HCW = health-care workers.*
negative nonfermenting bacilli are often spread through

closely linked to person-to-person spread, whereas gram-
nursing homes are the main reservoir (50). Second, the modes

acute-care hospitals (especially intensive care units) and

containing extended-spectrum beta-lactamase enzymes,

facilities (49). For others, such as gram-negative bacilli

dramatically. For some, like MRSA, the reservoir is now in

First, the reservoir for important resistant organisms varies

set policy in pharmacy and therapeutics committees. Thus,

administrative staff who provide direct care to patients and

prescribers, pharmacists, drug delivery personnel, and

updated (47,48).

for adverse effects have been undertaken and recently

Ability of the clinical microbiology laboratory to detect and

report resistance. Several new resistance mechanisms in

gram-positive and gram-negative bacterial organisms are
difficult to detect with usual laboratory methods. To counter

these problems, the National Committee for Clinical

Laboratory Standards (Villanova, Pennsylvania) and other

groups have developed new testing methods, as well as
guidelines and standards for testing resistant organisms (45).

Costs associated with these efforts are usually borne by the

health-care system, whether or not the tests are performed in-
house. Patients and society ultimately bear these costs,
depending on the mechanism by which the health-care system

is paid.

Educational Programs

Physicians, students, residents, nurses, pharmacists,
infection control and quality assurance personnel, adminis-
trative staff, and others are frequently part of the health-care

team. Making sure that awareness of the problem of

antimicrobial-drug resistance and how to deal with it are part

of the educational program or in-service education offerings is

a key part of obtaining support to minimize resistance. Costs

here result from the time needed to prepare and deliver

educational presentations and for attendees to participate;

these costs are primarily borne by the health-care system.

Optimizing Antimicrobial Agent Administration

The way that antimicrobial agents are prescribed is a

major risk determinant for resistance (46). Programs to

monitor and improve procedures for proper dosing, interval

of administration, duration of treatment, and monitoring for

adverse effects have been undertaken and recently

updated (47,48).

The economic impact relates to the time and efforts of

prescribers, pharmacists, drug delivery personnel, and

administrative staff who provide direct care to patients and

set policy in pharmacy and therapeutics committees. Thus,

health-care institutions are primarily affected by these

attempts to minimize antimicrobial-drug resistance. The

combination of measures must be individualized to the

particular organism-antimicrobial pair, health-care institu-
tion, and specific care setting, for at least two reasons (47).

First, the reservoir for important resistant organisms varies
dramatically. For some, like MRSA, the reservoir is now in

persons in some communities as well as in health-care

facilities (49). For others, such as gram-negative bacilli

containing extended-spectrum beta-lactamase enzymes,

acute-care hospitals (especially intensive care units) and

nursing homes are the main reservoir (50). Second, the modes

by which different organisms are spread differ. MRSA seems
closely linked to person-to-person spread, whereas gram-
negative nonfermenting bacilli are often spread through

contaminated liquids and respiratory therapy devices. Thus,

assessment of economic impact of measures to minimize

resistance depends on the specific measures that must be

introduced in a given institution or setting.

Influencing Drug Choice

Recent interest has focused on improving antimicrobial-
drug use by controlling the choice of antimicrobial agents by

individual prescribers. Some reported efforts attempt to limit

use of inappropriate agents by removing specific drugs from

the list of available agents in the formulary or restricting

them to certain specialists (51,52). Practice guidelines are a

means of achieving uniformity of antimicrobial-drug use that

have been applied to many areas in addition to that of

infectious diseases. Project ICARE (Intensive Care Anti-
microbial Drug Resistance Epidemiology) is a cooperative

project of the National Nosocomial Infections System of the

Centers for Disease Control and Prevention and the Rollins

School of Public Health of Emory University. A 1998 survey of
47 hospitals participating in Project ICARE showed that

clinical practice guidelines were reported frequently (70% of

hospitals) among measures to improve prescribing practices
(53). Guidelines are particularly useful in reducing costs of

therapy and total costs of prescription, while maintaining

quality of care (54). The question is whether these efforts can
reduce prevalence of antimicrobial-drug resistance; major

successes have been noted in recent studies, both in the

community and hospital (54).

Status of Methods and Results

Measurement of the economic impact of strategies to

minimize resistance is imprecise and incomplete (55). Some

information is available about the impact of these measures

on drug cost and length of hospital stay, number of diagnostic
tests, and number of therapeutic drugs used. Further work

needed includes designation or identification of optimal

methods for measurement, inclusion of more aspects of
economic impact, and carefully defining the perspective from

which the assessment is being made.

Conclusions

Determining the true economic impact of antimicrobial-
drug resistance is a challenge because so many variables and

perspectives are involved. Better methods are needed to

assess the practical implications for those from all

perspectives, whether prescriber, patient, health-care

business, pharmaceutical company, or the public. Because

studies completed to date have been hampered by their small

size and lack of uniformity, validity of the information

provided is unclear and extrapolating the studies to regional

or national or international levels is questionable.

Population-based studies of the true impact of resistance

would require large multicenter study groups and would be

valuable to help address the different perspectives. Relevant

studies will require sufficient size to describe baseline

antimicrobial-drug resistance, deal with limits of random

variation, and control for variables. Multicenter study groups

will likely have to be assembled to provide enough

observations, as well as sufficient resources. Only when this is

done can there be adequate exploration of the true magnitude

of the economic impact of antimicrobial-drug resistance.

The economic impact of antimicrobial-drug resistance
deserves more attention from government and professional

societies. Neither the summary of the Report by the American Society for Microbiology Task Force on Antibiotic Resistance nor the National Coalition on Antibiotic Resistance mentions this as an important area for study or as a concern for health care (32,56). A draft public health action plan to combat antimicrobial-drug resistance published by the federal Interagency Task Force on Antimicrobial Drug Resistance notes that costs of treating resistant infections place a substantial burden on society and mentions the impact of in-hospital cost of six common kinds of resistant bacteria (57).

As the U.S. health-care system has evolved into a business in the past decade, administrators concerned with cost and benefit have become important decision makers. Thus, economic arguments are needed to convince health-system administrators that antimicrobial-drug resistance is a serious issue. The same considerations apply in other countries as well (58). Lack of attention means that funding to solve the problems is unlikely to be found. A change in perception and action is needed to give this important issue of the economic impact of antimicrobial-drug resistance the priority it deserves.

Dr. McGowan is professor of epidemiology and of medicine (infectious diseases) at Emory University. His research interests focus on antimicrobial-drug resistance and its relation to antimicrobial-drug use.

References